Ontipria (Tiotropium Bromide)

Tiotropium bromide selectively blocks M3 muscarinic receptors on airway smooth‑muscle cells, preventing acetylcholine‑induced constriction. This inhibition produces sustained bronchodilation for up to 24 hours, improving airflow and reducing airway resistance in patients with chronic obstructive airway disease.

The prescribed dose of Ontipria is determined by a qualified healthcare professional based on the patient’s condition, age, and response to therapy. The prescriber will select the appropriate inhalation strength and dosing schedule according to clinical guidelines.

Safety data for tiotropium bromide in pregnancy are limited. It should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as small amounts may be excreted in milk.

To order Ontipria, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ontipria (tiotropium) is a long‑acting anticholinergic, offering once‑daily dosing and sustained bronchodilation. Compared with short‑acting agents, it provides more consistent airway support, and unlike some long‑acting beta‑agonists, it has a different mechanism that can be combined for additive effect when needed.

Store Ontipria at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the inhaler device clean and follow the manufacturer’s instructions for cartridge replacement.

Ontipria is delivered via a dry‑powder inhaler. The patient inhales a measured dose of powder through the mouthpiece, typically once daily, after exhaling fully and sealing lips around the device. Proper inhalation technique is essential for optimal drug delivery.

Serious adverse events, although rare, include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, and acute urinary retention. Patients should seek immediate medical attention if they experience sudden breathing difficulty, swelling of the face or throat, or inability to urinate.

Ontipria is contraindicated in individuals with a known hypersensitivity to tiotropium bromide or any inhaler components. Caution is advised for patients with narrow‑angle glaucoma, significant urinary retention, or those taking other anticholinergic medications.